Where does Palvella Therapeutics's cash flow data come from?

Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$49.3M-138%	-$41.72M-177%	-$35.07M-218%	-$26.61M-222%	-$20.73M-171%
Stock-based compensation	$8.68M+388%	$6.4M+671%	$4.59M—	$2.99M—	$1.78M—
Change in accounts payable	——	——	——	$2.97M+585%	$3.28M+305%
Change in accrued liabilities	——	——	——	——	——
Change in other assets	-$188K-125%	-$1.36M-191%	$118K-32.5%	$434K+1,678%	$738K+385%
Loss on extinguishment of debt	——	——	——	——	——
Change in operating lease liabilities	——	——	——	——	——
Net cash from operating activities	-$29.1M-76.3%	-$25.01M-131%	-$25.47M—	-$20.34M—	-$16.51M—
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of common stock	$230.76M—	$763K—	$658K—	$416K—	$0—
Other financing activities	——	——	——	——	——
Payment of debt issuance costs	——	——	——	——	——
Net cash from financing activities	——	——	——	——	$85.89M—
Effect of exchange rate changes on cash	——	——	$659K+979%	-$111K+73.1%	-$3K+98.5%
Net increase (decrease) in cash	$130.77M+87.6%	-$25.62M-133%	$49.36M+1,068%	$56.23M+819%	$69.71M+739%
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Accounts payable	——	——	——	$2.97M+585%	$3.28M+305%
Accrued expenses and other liabilities	——	——	——	——	——
Increase Decrease In Derivative Liabilities	$435K-33.1%	$394K-37.8%	$504K+78.2%	$497K+475%	$650K+313%
Operating lease liabilities	——	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	-$188K-125%	-$1.36M-191%	$118K-32.5%	$434K+1,678%	$738K+385%
Payments Of Stock Issuance Costs	——	$154K—	$115.5K—	$77K—	$38.5K—
Cash Acquired From Reverse Merger Transaction	——	$0-100%	$3.45M-66.7%	$6.9M0.0%	$10.35M+200%
Increase Decrease In Operating Lease Liability	——	——	——	——	——
Increase Decrease In Research And Development Tax Credit Receivables	——	-$2.11M-206%	-$1.08M-173%	-$63.5K-106%	$957.25K+93.6%
Non Cash Lease Operating Expense	——	——	——	——	$0—
Noncash Interest Expense Income Royalty Agreement	——	——	——	——	$4.13M+211%
Payment For Contingent Consideration Liability Financing Activities	——	——	——	——	——
Payments Of Merger Related Costs Financing Activities	——	——	——	——	$3.74M—
Payments Of Transaction Costs Associated With Pipe Financing	——	$0-100%	$635.5K-66.7%	$1.27M0.0%	$1.91M+200%
Transaction Costs Related To Reverse Merger Included In Accounts Payable And Accrued Expenses	——	$0-100%	$317.25K-66.7%	$634.5K0.0%	$951.75K+200%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Palvella Therapeutics's cash flow data come from?: Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.